5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 801–900 of 1,028
García, M. Á., Carrasco, E., Aguilera, J., Alvarez, P. J., Rivas, C., Rosa, J. M. C., Prados, J. C., Calleja, M. Á., Estéban, M., Marchal, J. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023887 · Cited by 70
“These metabolites have been implicated in both global RNA metabolism due to the incorporation of the ribonucleotide FUMP into RNA, and DNA metabolism due to thymidylate synthase (TS) inhibition or direct incorporation of FdUMP into DNA, leading to a wide range of biological effects which can act as triggers for apopto…”
BackgroundHu, Z., Lv, G., Li, Y., Li, E., Li, H., Zhou, Q., Yang, B., & Cao, W. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0349-4 · Cited by 60
“DNA processing and thymidylate synthase [4].”
BackgroundNK Cells Control Tumor-Promoting Function of Neutrophils in Mice
Ogura, K., Sato‐Matsushita, M., Yamamoto, S., Hori, T., Sasahara, M., Iwakura, Y., Saiki, I., Tahara, H., & Hayakawa, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0204 · Cited by 65
“The antimetabolite 5-FU acts as an anticancer drug by targeting DNA replication (39) and inducing systemic neutropenia (40).”
BackgroundJiang, H., Shi, X., Yu, X., He, X., An, Y., & Lu, H. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2302-4 · Cited by 59
“5-fluorouracil (5-FU), a pyrimidine analog is one of the important and broad spectrum anticancer drugs indicated in the treatment of several cancers including breast cancers, glioblastoma and colon cancers (4).”
BackgroundMultipurpose Intraperitoneal Adhesive Patches
Ryu, J. H., Kim, H. J., Kim, K., Yoon, G., Wang, Y., Choi, G., Lee, H., & Park, J. S. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201900495 · Cited by 60
The evolution of hematopoietic cells under cancer therapy
Pich, O., Cortes-Bullich, A., Muiños, F., Pratcorona, M., Gonzalez-Perez, A., & Lopez-Bigas, N. (2021) · Nature Communications · doi:10.1038/s41467-021-24858-3 · Cited by 60
Alasmari, A., Khan, A. Q., Al-Qasim, A. M., & Al-Yousef, Y. (2015) · Toxicology Reports · doi:10.1016/j.toxrep.2015.06.006 · Cited by 61
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem
Vaghari-Tabari, M., Majidinia, M., Moein, S., Qujeq, D., Asemi, Z., Alemi, F., Mohamadzadeh, R., Targhazeh, N., Safa, A., & Yousefi, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118255 · Cited by 58
Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
Pellacani, C., & Eleftheriou, G. (2020) · Advances in Medical Sciences · doi:10.1016/j.advms.2020.04.001 · Cited by 60
Molecular mechanisms associated with chemoresistance in esophageal cancer
Lohan-Codeço, M., Barambo-Wagner, M. L., Nasciutti, L. E., Pinto, L. F. R., Costa, N. M. D., & Palumbo, A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04131-6 · Cited by 67
“Considering its role in chemotherapy metabolism, higher levels of TP may increase the 5-FU effect mediating FdUMP synthesis [76, 77].”
BackgroundInfluentialA review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment
Yang, X., & Zhang, B. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01117-w · Cited by 63
“5-fluorouracil was widely used for treating different cancers, including colorectal cancer and breast cancer (Longley et al. 2003).”
BackgroundBanudevi, S., Sethuraman, S., & Krishnan, U. M. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00043 · Cited by 58
Stapleford, K. A., Rozen-Gagnon, K., Das, P. K., Saul, S., Poirier, E. Z., Blanc, H., Vidalain, P., Merits, A., & Vignuzzi, M. (2015) · Journal of Virology · doi:10.1128/jvi.01553-15 · Cited by 58
“in dTTP and increases in dUTP (16) and thus another imbalance”
BackgroundWilson, P. M., El-Khoueiry, A. B., Iqbal, S., Fazzone, W., LaBonte, M. J., Groshen, S. G., Yang, D., Danenberg, K. D., Cole, S., Kornacki, M., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1236-x · Cited by 61
“5-FU is reported to induce cellular toxicity by inhibiting the enzyme thymidylate synthase (TS) and through the incorporation of fluoronucleotides into RNA and DNA leading to thymidylate depletion, cell cycle arrest and apoptosis [ 7 ].”
BackgroundKenny, L. M., Contractor, K. B., Stebbing, J., AL-NAHHAS, A. M., Palmieri, C., Shousha, S., Coombes, R. C., & Aboagye, E. O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1213 · Cited by 58
Berchtold, S., Lampe, J. W., Weiland, T., Smirnow, I., Schleicher, S., Handgretinger, R., Kopp, H., Reiser, J., Stubenrauch, F., Mayer, N., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02106-12 · Cited by 68
“Further metabolites of 5-FU then inhibit thymidylate synthase or are incorporated into DNA and RNA, thereby interfering with DNA, RNA, and protein synthesis (31).”
BackgroundAshwanikumar, N., Kumar, N. A., Nair, S. A., & Kumar, G. S. V. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.07.024 · Cited by 58
Pardini, B., Rosa, F., Barone, E., Di Gaetano, C., Slyskova, J., Novotny, J., Levy, M., Garritano, S., Vodickova, L., Buchler, T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0314 · Cited by 58
“5-FU is widely employed in the treatment of a variety of solid tumors, including CRC (9).”
Lee, Y.-J., Urban, J. H., Xu, L., Sullenger, B. A., & Lee, J. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0575 · Cited by 63
“Fluorouracil is a pyrimidine analog and broadly used as an anticancer agent that induces apoptosis by inhibiting DNA and RNA synthesis [38].”
BackgroundCamacho, K. M., Menegatti, S., Vogus, D. R., Pusuluri, A., Fuchs, Z., Jarvis, M., Zakrewsky, M., Evans, M. A., Chen, R., & Mitragotri, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.027 · Cited by 63
Ye, L., Jiang, T., Shao, H., Zhong, L., Wang, Z., Liu, Y., Tang, H., Qin, B., Zhang, X., & Fan, J. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.05.006 · Cited by 66
“5-Fluorouracil (5-FU)-based adjuvant therapy is the first-line therapy for treating colon cancer and improves overall and disease-free survival of patients with advanced colon cancer.(2) However, the response rates of patients with advanced colon cancer are only 10%–50% because of chemoresistance.”
BackgroundRehman, M., Ihsan, A., Madni, A., Bajwa, S. Z., Shi, D., Webster, T. J., & Khan, W. S. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s147506 · Cited by 59
“32 In addition, the cytotoxicity of SLNs was lower than the cytotoxicity induced by the same concentration of 5-FU solution (Figure 7B).”
In Silico Prediction of Small Molecule-miRNA Associations Based on the HeteSim Algorithm
Qu, J., Chen, X., Sun, Y., Zhao, Y. F., Cai, S., Ming, Z., You, Z., & Li, J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.12.002 · Cited by 62
DNA folds threaten genetic stability and can be leveraged for chemotherapy
Zell, J., Sperti, F. R., Britton, S., & Monchaud, D. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00151a · Cited by 62
Singleton, P. A., Garcia, J. G. N., & Moss, J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2217 · Cited by 58
“Leucovorin enhances the binding of 5-FU to thymidylate synthetase and prolongs the lifespan of 5-FU in vivo (44).”
BackgroundInfluentialLiu, J., Liu, K., Zhang, L., Zhong, M., Hong, T., Zhang, R., Gao, Y., Li, R., Xu, T., & Xu, Z. P. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.011 · Cited by 60
Khajeh, A., & Modarress, H. (2014) · Biophysical Chemistry · doi:10.1016/j.bpc.2014.01.004 · Cited by 57
Xian, C. J., Cool, J. C., Pyragius, T., & Foster, B. K. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20889 · Cited by 70
“adult cancer patients (with colorectal or breast cancers or cancers of the aerodigestive tract) [Peters et al., 2000; Longley et al., 2003], but also used in treating childhood solid tumours, including head and neck cancers, hepatoblastoma, colon cancer, nasopharyngeal carcinoma, esophageal/gastric junction adenocarci…”
BackgroundInfluentialTerrazzino, S., Agostini, M., Pucciarelli, S., Pasetto, L. M., Friso, M. L., Ambrosi, A., Lisi, V., Leon, A., Lise, M., & Nitti, D. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230412.89973.c0 · Cited by 57
Immunomodulatory and Antitumor Activities of Grape Seed Proanthocyanidins
Tong, H., Song, X., Sun, X., Sun, G., & Du, F. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf203170k · Cited by 58
Hepatocellular Carcinoma and Chemotherapy: The Role of p53
Brito, A., Abrantes, A. M., Pinto-Costa, C., Gomes, A. R., Mamede, A. C., Casalta‐Lopes, J., Gonçalves, A. C., Sarmento‐Ribeiro, A. B., Tralhão, J. G., & Botelho, M. F. (2012) · Chemotherapy · doi:10.1159/000343656 · Cited by 58
Ali, J. A. M., Creek, D. J., Burgess, K. E., Allison, H. C., Field, M. C., Mäser, P., & de Koning, H. P. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.082321 · Cited by 58
“This is very different from 5-FU metabolism in human cells (Longley et al., 2003), where 5-FU incorporation into deoxynucleotides is mediated by human ribonucleotide reductase and by uridine phosphorylase and pyrimidine phosphorylase fol-”
InfluentialLiu, W., Fang, Y., Wang, X., Liu, J., Dan, X., & Sun, L. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.17.7037 · Cited by 57
“5-fluorouracil (5-Fu) is a chemotherapeutic drug used worldwide in the treatment of metastatic colorectal cancer, either alone or in combination with other chemotherapeutic agents (Herrmann, 1996; Longley et al., 2003).”
Miyakoshi, H., Miyahara, S., Yokogawa, T., Endoh, K., Muto, T., Yano, W., Wakasa, T., Ueno, H., Chong, K. T., Taguchi, J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3004174 · Cited by 58
Kumari, S., & Kondapi, A. K. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.10.110 · Cited by 57
Russo, A., Maiolino, S., Pagliara, V., Ungaro, F., Tatangelo, F., Leone, A., Scalia, G., Budillon, A., Quaglia, F., & Russo, G. (2016) · Oncotarget · doi:10.18632/oncotarget.13216 · Cited by 58
“Although 5-FU is an old anticancer drug, it is still used as first line therapy in the treatment of colon cancer [24].”
BackgroundAnand, S., Rollakanti, K. R., Brankov, N., Brash, D. E., Hasan, T. G., & Maytin, E. V. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0608 · Cited by 58
“Another phenomenonwe observed in this study, an increase in p53 in A431 tumors pretreated with 5-FU, was consistent with previous work showing that 5-FU exposure leads to incorporation of fluorodeoxyuridine triphosphate (FdUTP) into DNA, and fluorouridine triphosphate into RNA, triggering DNA-damage and RNA-damage res…”
BackgroundInfluentialKim, S.-H., Kim, S., & Ku, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17798 · Cited by 61
“Despite the usage frequency, 5-Fu has low effectiveness in colorectal cancer at about 10 to 15% [2].”
Köke, N., Zahn, D., Knepper, T. P., & Frömel, T. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-0921-1 · Cited by 62
Mechanisms of Anticancer Drug Resistance in Hepatoblastoma
Marín, J. J. G., Cives-Losada, C., Asensio, M., Lozano, E., Briz, Ó., & Macías, R. I. R. (2019) · Cancers · doi:10.3390/cancers11030407 · Cited by 60
“to the lack of response to 5-FU [133] (MOC-5).”
BackgroundMutharani, B., Ranganathan, P., & Chen, S. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.127361 · Cited by 58
Zoetemelk, M., Ramzy, G. M., Rausch, M., & Nowak-Sliwinska, P. M. (2020) · Molecules · doi:10.3390/molecules25112614 · Cited by 61
“Simultaneously, the metabolite 5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) inhibits the enzyme thymidylate synthase, which orchestrates the main reactions providing thymidylate, necessary for DNA replication and repair, see Figure 1B [10].”
BackgroundRodrigues, D., de Souza, T. M., Coyle, L., Piazza, M., Herpers, B., Ferreira, S., Zhang, M., Vappiani, J., Sévin, D. C., Gábor, A., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03092-2 · Cited by 61
“This is concordant with the known main mechanism of action of 5-FU, namely the incorporation of fluoronucleotides into DNA and RNA molecules (Longley et al. 2003), which perturbs DNA and RNA synthesis (Lee et al.”
BackgroundInfluentialTakeda, I., Maruya, S.-I., Shirasaki, T., Mizukami, H., Takahata, T., Myers, J. N., Kakehata, S., Yagihashi, S., & Shinkawa, H. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00471.x · Cited by 64
Silverstein, R. A., de Valdivia, E. G., & Visa, N. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0084 · Cited by 66
Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a
Li, Y., Lv, S., Ning, H., Li, K., Zhou, X., Xv, H., & Wen, H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.181 · Cited by 56
Smart Injectable Chitosan Hydrogels Loaded with 5-Fluorouracil for the Treatment of Breast Cancer
Abdellatif, A. A. H., Mohammed, A. M., Saleem, I. Y., Alsharidah, M. S., Rugaie, O. A., Ahmed, F., & Osman, S. K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030661 · Cited by 59
Lei, L., Dong, Z., Li, X., Yang, F., Yin, B., Wang, Y., Yue, R., Guan, G., Xu, J., Song, G., et al. (2022) · Theranostics · doi:10.7150/thno.75323 · Cited by 58
“Although Fu induced chemotherapy has been demonstrated to induce ICD in tumor cells, the unsatisfactory immune response and inevitable toxic side effects were observed in vivo, because of the drug resistance and low selectivity [23-26].”
Background“Double-Edged Sword” Effect of Reactive Oxygen Species (ROS) in Tumor Development and Carcinogenesis
Zhao, W., Zhuang, P., Chen, Y., Wu, Y. L., Zhong, M., & Lun, Y. (2023) · Physiological Research · doi:10.33549/physiolres.935007 · Cited by 65
Knikman, J. E., Wilting, T. A., López‐Yurda, M., Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Nieboer, P., Droogendijk, H. J., Creemers, G., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02780 · Cited by 56
Role of stress granules in tumorigenesis and cancer therapy
Li, T., Zeng, Z., Fan, C., & Xiong, W. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189006 · Cited by 64
Ochratoxin A and Its Role in Cancer Development: A Comprehensive Review
Więckowska, M., Cichoń, N., Szelenberger, R., Gorniak, L., & Bijak, M. (2024) · Cancers · doi:10.3390/cancers16203473 · Cited by 56
“Studies suggest that OTA can intensify the cytotoxic effects of 5-FU, particularly in renal tissue, where OTA accumulation and oxidative stress are elevated, thereby increasing the potential for renal injury [173,174].”
BackgroundScala, F., Brighenti, E., Govoni, M., Imbrogno, E., Fornari, F., Treré, D., Montanaro, L., & Derenzini, M. (2015) · Oncogene · doi:10.1038/onc.2015.147 · Cited by 60
Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action
Shaaban, S., Negm, A., Ibrahim, E. E., & Elrazak, A. A. (2014) · Oncology Reviews · doi:10.4081/oncol.2014.246 · Cited by 73
Gotanda, K., Hirota, T., Matsumoto, N., & Ieiri, I. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-369 · Cited by 56
“Five-fluorouracil (5-FU), one of several TYMS inhibitors, is widely used to induce temporary tumor regression and improve survival, especially for gastrointestinal cancers [2].”
BackgroundLi, C., Penet, M., Wildes, F. B., Takagi, T., Chen, Z., Winnard, P. T., Artemov, D., & Bhujwalla, Z. M. (2010) · ACS Nano · doi:10.1021/nn102187v · Cited by 56
“The liver contains high levels of dihydropyrimidine dehydrogenase, which rapidly catabolizes 5-FU to dihydrofluorouracil.(45) Liver or kidney necrosis was not observed previously(13) or in the current study.”
Shibata, E., Dar, A., & Dutta, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.574210 · Cited by 56
“In a range of human cancers, such as colorectal, gastrointestinal, breast, and ovarian, 5-FU (uracil analog) is used as the first line of treatment (7, 8).”
BackgroundPereira, D. M., Simões, A. E. S., Gomes, S. E., Castro, R. E., Carvalho, T., Rodrigues, C. M. P., & Borralho, P. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9107 · Cited by 58
“The p53 tumor suppressor is a major determinant of the balance between cell cycle arrest and apoptosis following 5-FU exposure [15].”
BackgroundInfluentialCardullo, N., Pulvirenti, L., Spatafora, C., Musso, N., Barresi, V., Condorelli, D. F., & Tringali, C. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b00577 · Cited by 57
miR-20b reduces 5-FU resistance by suppressing the ADAM9/EGFR signaling pathway in colon cancer
Fu, Q., Cheng, J., Zhang, J., Zhang, Y., Chen, X., Luo, S., & Xie, J. (2016) · Oncology Reports · doi:10.3892/or.2016.5259 · Cited by 60
“5-Fluorouracil (5-FU) is a mainstream chemotherapeutic drug that is widely used in CC treatment (2,3).”
Backgroundl-arginine alters the effect of 5-fluorouracil on breast cancer cells in favor of apoptosis
Jahani, M., Azadbakht, M., Norooznezhad, F., & Mansouri, K. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.047 · Cited by 65
Han, J., Li, J., Tang, K., Zhang, H., Guo, B., Hou, N., & Huang, C. Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.023 · Cited by 56
The potential of exosomes derived from colorectal cancer as a biomarker
Xiao, Y., Li, Y., Yuan, Y., Liu, B., Pan, S., Liu, Q., Qi, X., Zhou, H., Dong, W., & Li, J. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.007 · Cited by 57
De Jesus, L. C. L., Drumond, M. M., de Carvalho, A., Santos, S. S., Martins, F. S., Ferreira, Ê., Fernandes, R. S., de Barros, A. L. B., do Carmo, F. L. R., Perez, P. F., et al. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2018.12.027 · Cited by 57
Wei, R., Wirkus, J., Yang, Z., Machuca, J., Esparza, Y., & Mackenzie, G. G. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108546 · Cited by 62
“Furthermore, 5-FU is associated with health risks, ranging from nausea and diarrhea to neurological disorders and myelosuppression [2, 3].”
BackgroundHistory and emerging trends in chemotherapy for gastric cancer
Yamashita, K., Hosoda, K., Niihara, M., & Hiki, N. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12439 · Cited by 67
Nagaraja, K., Rao, K. M., Reddy, G. V., & Rao, K. S. V. K. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.203 · Cited by 58
Wilson, P. M., Fazzone, W., LaBonte, M. J., Lenz, H., & Ladner, R. D. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn910 · Cited by 64
“As a single agent, oxaliplatin has limited clinical activity in colorectal cancer and is primarily used in combination with 5-FU or capecitabine resulting in synergistic antitumor activity (3,37,61).”
BackgroundLongley, D. B., Allen, W. L., McDermott, U., Wilson, T. R., Latif, T., Boyer, J. D., Lynch, M., & Johnston, P. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0532 · Cited by 57
“The 5-FU metabolite fluorodeoxyuridine monophosphate forms a stable complex with TS and 5,10-methylene tetrahydrofolate, resulting in enzyme inhibition (1).”
BackgroundSelf-citationKim, C. W., Chon, H. J., & Kim, C. (2021) · Cancers · doi:10.3390/cancers13194906 · Cited by 58
Recent advances in the discovery of copper(II) complexes as potential anticancer drugs
Rogalewicz, B., & Czylkowska, A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117702 · Cited by 58
Medicinal Chemistry of Fluorinated Cyclic and Acyclic Nucleoside Phosphonates
Baszczyňski, O., & Janeba, Z. (2013) · Medicinal Research Reviews · doi:10.1002/med.21296 · Cited by 57
Ma, X., Cheng, Z., Jin, Y., Liang, X., Yang, X., Dai, Z., & Tian, J. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.045 · Cited by 55
ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer
Pańczyk, M., Balcerczak, E., Piaskowski, S., Jamroziak, K., Pasz‐Walczak, G., & Mirowski, M. (2009) · International Journal of Colorectal Disease · doi:10.1007/s00384-009-0724-0 · Cited by 55
“The genotoxic stress resulting from 5-FU administration may activate apoptosis in susceptible cells via activated P53 or inactivated cyclin-dependent kinases [49].”
BackgroundTargeting Metabolic Changes in Cancer: Novel Therapeutic Approaches
Bobrovnikova-Marjon, E. V., & Hurov, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112344 · Cited by 58
Pinzón‐Daza, M. L., Cuellar, Y., Nualart, F., Ondo-Méndez, A., Prendes, L. D. R., Castillo‐Rivera, F., & Garzón, R. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25890 · Cited by 59
“Different drug combinations, such as the following, have been used for colon cancer treatment: fluorouracil [Longley et al., 2003], doxorubicin, and mitomycin C or methotrexate [Weinl€ander et al., 1997]; etoposide, doxorubicin, and cisplatin and docetaxel and cisplatin with/without fluorouracil…”
MethodRole of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells
Russo, A., Saide, A., Smaldone, S., Faraonio, R., & Russo, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030547 · Cited by 56
“To exert its cytotoxic effects, 5-FU is converted to its active metabolites by several enzymes and the levels of these enzymes have been associated with 5-FU sensitivity [6].”
BackgroundDesign, synthesis of new pyrimidine derivatives as anticancer and antimicrobial agents
Mohamed, M. M., Khalil, A. K., Abbass, E. M., & El‐Naggar, A. M. (2017) · Synthetic Communications · doi:10.1080/00397911.2017.1332223 · Cited by 55
“5-FU induces cell kill mainly through destructing DNA synthesis by inhibiting dTMP synthase which is the enzyme that catalyses the conversion of dUMP to deoxythymidylate.([23]) Molecular docking comparing the binding affinity of 5-FU and thiouracil derivatives was therefore conducted.”
BackgroundPrediction of Potential Small Molecule-Associated MicroRNAs Using Graphlet Interaction
Guan, N., Sun, Y., Ming, Z., Li, J., & Chen, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01152 · Cited by 55
Zhang, M., Fan, Y., Che, X., Hou, K., Zhang, C., Li, C., Wen, T., Wang, S., Cheng, Y., Liu, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00492 · Cited by 57
“5-FU kills tumor cells through misincorporation of fluoronucleotides into DNA and RNA molecules and by inhibition of the nucleotide synthesis enzyme thymidylate synthase (TS) (6).”
BackgroundLuo, L., Zhang, J., Tang, H., Zhai, D., Huang, D., Li, L., Wang, X., Liu, T., Zhang, Q., Zhang, Z., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2557-2 · Cited by 55
Zhao, J., Fu, X., Chen, H., Min, L., Sun, J., Yin, J., Guo, J., Li, H., Tang, Z., Ruan, Y., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-020-01067-1 · Cited by 60
The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer
Warusavitarne, J. H., & Schnitzler, M. (2006) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0228-0 · Cited by 56
“The RNA directed effects of 5FU results in disrupting post-transcriptional modifications of tRNA and inhibition of the processing of rRNA [60].”
InfluentialAlkhalifah, M. A., Yar, M., Bayach, I., Sheikh, N. S., & Ayub, K. (2022) · Materials · doi:10.3390/ma15217425 · Cited by 54
“In the initial step, 5-FU exerts its anticancer effects through the inhibition of thymidylate synthase (TS) and the incorporation of its metabolites into DNA (see Figure 1) [72].”
BackgroundIFNγ-Stat1 axis drives aging-associated loss of intestinal tissue homeostasis and regeneration
Omrani, O., Křepelová, A., Rasa, S. M. M., Širvinskas, D., Lu, J. N., Annunziata, F., Garside, G. B., Bajwa, S., Reinhardt, S., Adam, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41683-y · Cited by 64
Zhang, X., Chen, W., Wan, S., Qu, B., Liao, F., Cheng, D., Zhang, Y., Ding, Z., Yang, Y., & Yuan, Q. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c16001 · Cited by 56
Gentile, G., Botticelli, A., Lionetto, L., Mazzuca, F., Simmaco, M., Marchetti, P., & Borro, M. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.56 · Cited by 54
Burdelski, C. M., Strauss, C., Tsourlakis, M. C., Kluth, M., Hube‐Magg, C., Melling, N., Lebok, P., Minner, S. J. P., Koop, C., Graefen, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3107 · Cited by 62
“The rapidly increasing evidence for a relevant role of TYMS in cancer is also of potential therapeutic interest since some of the widely used cytotoxic drugs including 5-fluorouracil (5-FU) and capecitabine exert their anticancer effects by inhibiting TYMS [51–53].”
Perveen, F., Qureshi, R., Ansari, F. L., Kalsoom, S., & Ahmed, S. (2011) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2011.07.027 · Cited by 54
Safeguarding Nonhuman Primate iPS Cells With Suicide Genes
Zhong, B., Watts, K. L., Gori, J. L., Wohlfahrt, M. E., Enssle, J., Adair, J. E., & Kiem, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.51 · Cited by 56
Can, G., Akpinar, B., Baran, Y., Zhivotovsky, B., & Olsson, M. (2012) · Oncogene · doi:10.1038/onc.2012.467 · Cited by 65
The Cell’s Nucleolus: an Emerging Target for Chemotherapeutic Intervention
Pickard, A. J., & Bierbach, U. (2013) · ChemMedChem · doi:10.1002/cmdc.201300262 · Cited by 59
Cohen, S., Jordheim, L. P., Megherbi, M., Dumontet, C., & Guitton, J. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.05.016 · Cited by 62
Pseudouridines in spliceosomal snRNAs
Yu, A., Ge, J., & Yu, Y. (2011) · Protein & Cell · doi:10.1007/s13238-011-1087-1 · Cited by 65
“However, except for the postulation that it affects DNA metabolism, the mechanism of action of 5FU remained largely unclear (Parker and Cheng, 1990; Ghoshal and Jacob, 1997; Longley et al., 2003).”
BackgroundLee, S. J., Kim, S. Y., Chung, J. H., Oh, S. J., Ryu, J. S., Hong, Y. S., Kim, T. W., & Moon, D. H. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.004 · Cited by 54
Wilson, P. M., LaBonte, M. J., Lenz, H., Mack, P. C., & Ladner, R. D. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0781 · Cited by 60
“Elevated intratumoral expression of TS is reported to limit the severity of TTP pool depletion leading to resistance to TS inhibitors (29, 44).”
BackgroundXu, H., Yang, T., Liu, X., Tian, Y., Chen, X., Yuan, R., Su, S., Lin, X., & Du, G. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.12.002 · Cited by 54
Cyclin D mediates tolerance of genome-doubling in cancers with functional p53
Crockford, A., Zalmas, L., Gronroos, E. C., Dewhurst, S. M., McGranahan, N., Cuomo, M. E., Encheva, V., Snijders, A. P., Begum, J., Purewal, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw612 · Cited by 56
“In order to confirm functional p53 signalling, diploid and tetraploid HCT116 clones were treated with 5-FU, a member of the fluoropyrimidine compound family known to activate p53 [16].”
The Exploitation of Low-Energy Electrons in Cancer Treatment
Rezaee, M., Hill, R. P., & Jaffray, D. A. (2017) · Radiation Research · doi:10.1667/rr14727.1 · Cited by 59
Fesler, A. T., Liu, H., & Ju, J. (2017) · Oncotarget · doi:10.18632/oncotarget.23414 · Cited by 56
“5-FU has been used for treatment of colon cancer for several decades [3].”
Background
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.